- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- WF-AO-OCT
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 1,622
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
- Interventions
- ocriplasmin 0.0625mg, ocriplasmin 0.125mg, Sham injection
- Drug
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Campbell, California • Irvine, California + 6 more
- Conditions
- Retinitis Pigmentosa, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy From Age-related Macular Degeneration, X-linked Retinoschisis, Retinal Dystrophies
- Interventions
- Not listed
- Lead sponsor
- Ray Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Inherited Retinal Diseases
- Interventions
- Low Vision Rehabilitation (LVR), Emotion Regulation Therapy (ERT)
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Epiretinal Membrane
- Interventions
- Nepafenac 0.1%, BSS
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Retinal Degenerations
- Interventions
- 2% dorzolamide
- Drug
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Macular Degeneration, Age-related, Geographic Atrophy
- Interventions
- BI 771716, Pegcetacoplan, Sham comparator to BI 771716
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- EYE001 anti-VEGF aptamer
- Drug
- Lead sponsor
- Eyetech Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Retinopathy of Prematurity
- Interventions
- RetCam retinal imaging used for routine care
- Procedure
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 32 Weeks to 40 Weeks
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 2 more
- Conditions
- Transthyretin Amyloid Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Jacksonville, Florida • Chicago, Illinois + 3 more
- Conditions
- Macular Degeneration
- Interventions
- GW786034, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Austin, Texas • Tacoma, Washington
- Conditions
- Choroidal Melanoma
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Retinoblastoma, Eye Cancer
- Interventions
- Intra-arterial infusion of chemotherapy
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 55 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Macular Degeneration
- Interventions
- Anecortave Acetate Sterile Suspension (15 mg)
- Drug
- Lead sponsor
- Manhattan Eye, Ear & Throat Hospital
- Other
- Eligibility
- 50 Years and older
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Retinitis Pigmentosa, Eye Diseases
- Interventions
- Not listed
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 13
- States / cities
- San Francisco, California • Denver, Colorado • Gainesville, Florida + 10 more
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy
- Interventions
- MS-R001 (rapamycin)
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Arlington, Texas
- Conditions
- Diabetic Retinopathy (DR)
- Interventions
- SaMD intended for the detection of diabetic retinopathy in adults with diabetes., An AI/ML-based Software as a Medical Device (SaMD) for the automated detection of diabetic retinopathy in adults with diabetes.
- Device
- Lead sponsor
- Digital Diagnostics, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Retinitis Pigmentosa
- Interventions
- Lutein (10 or 30 mg/day) capsules
- Drug
- Lead sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- NIH
- Eligibility
- Not listed
- Timeline
- 2001 – 2002
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
- Interventions
- High Dose NT-501 implant, Low Dose NT-501 implant, Sham
- Combination Product · Other
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Hollywood, Florida • Miami, Florida + 5 more
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Cystoid Macular Edema
- Interventions
- Not listed
- Lead sponsor
- Retina Institute of Hawaii
- Other
- Eligibility
- Up to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii